TCF21 loss identifies a conserved inflammation-associated fibroblast state across CD and UC, supporting stromal reprogramming as a therapeutic concept in IBD.
Mor Hindi Malowany, Noah Franklin, Matthew V. Russo et al.· bioRxiv· 0 citations
Immune checkpoint inhibitors improve outcomes for many patients with cancer, but resistance remains a major clinical challenge. Type 2 cytokines, including IL-4, IL-13, and thymic stromal lymphopoietin (TSLP), have been implicated in suppressing anti-tumor immunity. Here, we investigated whether combined blockade of IL...
T. Fabre, Eleanore Hendrickson, K. McGourty et al.· Cell Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.